Inventor · disambiguated record
Matthew Meyerson
Also filed as: MEYERSON MATTHEW · MEYERSON MATTHEW L
31 granted patents·21 pending applications·492 citations·filing 2001–2025
96Inventor score
Files withBAYER AG14BROAD INST INC13DANA FARBER CANCER INST INC12MASSACHUSETTS GEN HOSPITAL4Bayer Pharma AG3
Top patents by PatentIndex Score
52 records- 0198US7964349B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsGEN HOSPITAL CORP·Filed 2007·Granted Jun 21, 2011·92 cites·31 claims
- 0298US7294468B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsGEN HOSPITAL CORP·Filed 2005·Granted Nov 13, 2007·187 cites·8 claims
- 0396US8465916B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsBELL DAPHNE WINIFRED·Filed 2007·Granted Jun 18, 2013·85 cites·21 claims
- 0496US8105769B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsBELL DAPHNE WINIFRED·Filed 2007·Granted Jan 31, 2012·97 cites·4 claims
- 0594US11773070B2DihydrooxadiazinonesBAYER AG·Filed 2022·Granted Oct 3, 2023·2 cites·9 claims
- 0690US12258323B2DihydrooxadiazinonesBAYER AG·Filed 2022·Granted Mar 25, 2025·1 cites·15 claims
- 0790US11427553B2DihydrooxadiazinonesBAYER AG·Filed 2018·Granted Aug 30, 2022·4 cites·11 claims
- 0889US9035036B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsGEN HOSPITAL CORP·Filed 2013·Granted May 19, 2015·8 cites·26 claims
- 0988US11142522B2Compounds, compositions and methods for cancer treatmentBROAD INST INC·Filed 2018·Granted Oct 12, 2021·4 cites·16 claims
- 1083US2024366620A1Compounds, compositions and methods for cancer patient stratification and cancer treatmentBayer Pharma AG·Filed 2024·Application pending·0 cites
- 1181US9890127B2Compounds and compositions for the treatment of cancerBROAD INST INC·Filed 2014·Granted Feb 13, 2018·3 cites·12 claims
- 1281US6996477B2Computational subtraction methodDANA FARBER CANCER INST INC·Filed 2001·Granted Feb 7, 2006·5 cites·36 claims
- 1379US10966986B2Compounds, compositions and methods for cancer patient stratification and cancer treatmentBayer Pharma AG·Filed 2017·Granted Apr 6, 2021·1 cites·8 claims
- 1475US12006555B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsMASSACHUSETTS GEN HOSPITAL·Filed 2020·Granted Jun 11, 2024·0 cites·16 claims
- 1574US12053476B2Compounds, compositions and methods for cancer patient stratification and cancer treatmentBayer Pharma AG·Filed 2021·Granted Aug 6, 2024·0 cites·6 claims
- 1674US11339157B14H-pyrrolo[3,2-c]pyridin-4-one derivativesBAYER AG·Filed 2018·Granted May 24, 2022·2 cites·19 claims
- 1774US2024182452A16-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancerBAYER AG·Filed 2023·Application pending·0 cites
- 1873US11060148B2Diagnosing and treating colorectal cancerDANA FARBER CANCER INST INC·Filed 2013·Granted Jul 13, 2021·1 cites·18 claims
- 1973US10669589B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Jun 2, 2020·0 cites·13 claims
- 2071US2025136599A14h-pyrrolo[3,2-c]pyridin-4-one compoundsBAYER AG·Filed 2024·Application pending·0 cites
- 2167US9439909B2Compositions and methods for sensitizing a neoplastic cell to radiationBROAD INST INC·Filed 2014·Granted Sep 13, 2016·0 cites·18 claims
- 2267US2022071995A1Compositions and methods for cancer expressing pde3a or slfn12BROAD INST INC·Filed 2021·Application pending·0 cites
- 2365US11946105B2Bacterial etiology of colorectal cancerDANA FARBER CANCER INST INC·Filed 2021·Granted Apr 2, 2024·0 cites·4 claims
- 2465US9499856B2DDR2 mutations in squamous cell lung cancerBROAD INST INC·Filed 2013·Granted Nov 22, 2016·0 cites·24 claims
- 2565US2020087734A1DDR2 Mutations in Squamous Cell Lung CancerBROAD INST INC·Filed 2019·Application pending·0 cites
- 2664US2025352547A1Cancer Diagnostic and TreatmentDANA FARBER CANCER INST INC·Filed 2025·Application pending·0 cites
- 2764US2023405015A1Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcomaBAYER AG·Filed 2023·Application pending·0 cites
- 2862US2024109850A1Covalent PPARG inverse-agonistsBAYER AG·Filed 2023·Application pending·0 cites
- 2962US2024150277A1Covalent PPARG inverse-agonistsBAYER AG·Filed 2023·Application pending·0 cites
- 3061US10385403B2DDR2 mutations in squamous cell lung cancerBROAD INST INC·Filed 2016·Granted Aug 20, 2019·0 cites·12 claims
- 3160US11926874B2Methods for identification, assessment, prevention, and treatment of cancer using PD-L1 isoformsDANA FARBER CANCER INST INC·Filed 2019·Granted Mar 12, 2024·0 cites·12 claims
- 3260US2023416249A1N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancerBAYER AG·Filed 2023·Application pending·0 cites
- 3359US12239646B2Cancer diagnostic and treatmentDANA FARBER CANCER INST INC·Filed 2018·Granted Mar 4, 2025·0 cites·24 claims
- 3459US10000815B2Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsMASSACHUSETTS GEN HOSPITAL·Filed 2015·Granted Jun 19, 2018·0 cites·32 claims
- 3558US11207320B2Compositions and methods for cancer expressing PDE3A or SLFN12BROAD INST INC·Filed 2016·Granted Dec 28, 2021·0 cites·10 claims
- 3658US10449199B2Compositions and methods for sensitizing a neoplastic cell to radiationBROAD INST INC·Filed 2016·Granted Oct 22, 2019·0 cites·26 claims
- 3756US2023064983A13-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancerBAYER AG·Filed 2022·Application pending·0 cites
- 3854US2022298157A14h-pyrrolo[3,2-c]pyridin-4-one compoundsBAYER AG·Filed 2020·Application pending·0 cites
- 3953US11896678B2Compositions and methods for treatment of peroxisome proliferator-activated receptor gamma (PPARG) activated cancerBROAD INST INC·Filed 2018·Granted Feb 13, 2024·0 cites·15 claims
- 4053US2024165144A1Compositions and methods for modulating innate immune signaling pathwaysDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 4151US2015197785A1Methods and apparatus for analyzing and quantifying dna alterations in cancerBROAD INST INC·Filed 2013·Application pending·0 cites
- 4249US2022282333A1Methods for predicting outcomes of checkpoint inhibition and treatment thereofMASSACHUSETTS GEN HOSPITAL·Filed 2020·Application pending·0 cites
- 4348US12403135B24H-pyrrolo[3,2-c]pyridin-4-one derivativesBAYER AG·Filed 2020·Granted Sep 2, 2025·0 cites·16 claims
- 4447US11873486B2Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferonDANA FARBER CANCER INST INC·Filed 2018·Granted Jan 16, 2024·0 cites·18 claims
- 4547US2022364079A1Methods of high-throughput identification of t cell epitopes by capturing cytokines on the surface of antigen-presenting cellsDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 4647US2004009489A1Classification of lung carcinomas using gene expression analysisFiled 2002·Application pending·0 cites
- 4746US2024307362A14H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDSBAYER AG·Filed 2020·Application pending·0 cites
- 4845US10723753B2Ras inhibitors and uses thereofDANA FARBER CANCER INST INC·Filed 2014·Granted Jul 28, 2020·0 cites·39 claims
- 4945US2018244629A1Compounds And Compositions For The Treatment Of CancerBROAD INST INC·Filed 2018·Application pending·0 cites
- 5041US2019156913A1Methods of diagnosing and treating cancer by detection of chromosomal abnormalitiesDANA FARBER CANCER INST INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Matthew Meyerson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →